Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 4.

Article

Jaworski, J, Matucci-Cerinic, M, Schulze-Koops, H et al. (6 more authors) (2019) Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Research and Therapy, 21 (1). 130. ISSN 1478-6354

Matucci-Cerinic, M, Allanore, Y, Kavanaugh, A et al. (8 more authors) (2018) Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open, 4 (2). e000757. ISSN 2056-5933

Jaeger, VK, Wirz, EG, Allanore, Y et al. (96 more authors) (2016) Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLOS ONE, 11 (10). e0163894.

Proceedings Paper

Kavanaugh, A, Matucci-Cerinic, M, Schulze-Koops, H et al. (4 more authors) (2018) Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

This list was generated on Sat Nov 16 18:33:23 2019 GMT.